Hagiwara Ken'ichi, Nakamura Yuko, Nishijima Masahiro, Yamakawa Yoshio
Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Japan.
Biol Pharm Bull. 2007 Apr;30(4):835-8. doi: 10.1248/bpb.30.835.
In prion diseases, the normal cellular form of prion protein (PrP(C)) is converted into the disease-associated isoforms (PrP(Sc)) which accumulate in the infected tissues. Although the precise mechanism of this conversion remains unsolved, drugs of various categories have been reported to reduce the accumulation of PrP(Sc) in prion-infected cultured cells. We here show that AY-9944 (a 7-dehydrocholesterol reductase inhibitor) and U18666A (a 24-dehydrocholesterol reductase inhibitor) prevent PrP(Sc) from accumulating in prion-infected mouse neuroblastoma cells (ScN2a), with an ED50 of about 0.5 microM and 10 nM, respectively. In order to evaluate the efficacy of these two inhibitors in vivo, C57BL/6J mice inoculated with mouse-adapted scrapie-prion received repetitive intraperitoneal injections of U18666A (10 mg/kg) or a mixture of U18666A (10 mg/kg) and AY-9944 (12 mg/kg). By contrast to the potent anti-prion effects observed in ScN2a cells, the in vivo trial was abortive with neither drug halting the progression of the disease.
在朊病毒疾病中,正常细胞形式的朊病毒蛋白(PrP(C))会转化为与疾病相关的异构体(PrP(Sc)),后者在受感染组织中积累。尽管这种转化的确切机制仍未解决,但据报道,各类药物可减少PrP(Sc)在朊病毒感染的培养细胞中的积累。我们在此表明,AY - 9944(一种7 - 脱氢胆固醇还原酶抑制剂)和U18666A(一种24 - 脱氢胆固醇还原酶抑制剂)可防止PrP(Sc)在朊病毒感染的小鼠神经母细胞瘤细胞(ScN2a)中积累,其半数有效剂量(ED50)分别约为0.5微摩尔和10纳摩尔。为了评估这两种抑制剂在体内的疗效,接种了小鼠适应型羊瘙痒病朊病毒的C57BL/6J小鼠接受了U18666A(10毫克/千克)或U18666A(10毫克/千克)与AY - 9944(12毫克/千克)混合物的重复腹腔注射。与在ScN2a细胞中观察到的强效抗朊病毒作用形成对比的是,体内试验未成功,两种药物均未阻止疾病的进展。